Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland

被引:40
|
作者
Eerola, J
Launes, J
Hellström, O
Tienari, PJ
机构
[1] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland
[2] Univ Helsinki, Biomedicum, Neurosci Programme C524, Helsinki, Finland
[3] Seinajoki Cent Hosp, Dept Neurol, Seinajoki, Finland
关键词
Parkinson's disease; gene studies; Finland;
D O I
10.1016/S0304-3940(02)00819-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Recent studies have demonstrated that genetic factors modify susceptibility to sporadic Parkinson's disease (PD). So far the results of candidate gene studies have been conflicting. It has been suggested that polymorphisms in apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes might increase the risk of PD. We studied 147 Finnish non-demented patients with sporadic PD and 137 controls. APOEE allele and genotype frequencies in PD patients did not differ significantly from controls. Three single nucleotide polymorphisms of the PARKIN gene and an intronic and an exonic (Val158Met) polymorphism of the COMT gene were studied. None of these polymorphisms showed association with PD in our series. In contrast to reports in oriental populations, our results do not support a major role of APOE, PARKIN and COMT polymorphisms in PD susceptibility in the Finnish population. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:296 / 298
页数:3
相关论文
共 50 条
  • [1] Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease
    Waters, C
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (06) : 692 - 698
  • [2] Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population
    Bialecka, M
    Drozdzik, M
    Honczarenko, K
    Gawronska-Szklarz, B
    Stankiewicz, J
    Dabrowska, E
    Kubisiak, M
    Klodowska-Duda, G
    Opala, G
    [J]. EUROPEAN NEUROLOGY, 2005, 53 (02) : 68 - 73
  • [3] What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
    Salamon, Andras
    Zadori, Denes
    Szpisjak, Laszlo
    Klivenyi, Peter
    Vecsei, Laszlo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (10) : 1123 - 1128
  • [4] Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan
    A. Yoritaka
    N. Hattori
    H. Yoshino
    Y. Mizuno
    [J]. Journal of Neural Transmission, 1997, 104 : 1313 - 1317
  • [5] Catechol-O-methyltransferase and Parkinson's disease
    Tai, CH
    Wu, RM
    [J]. ACTA MEDICA OKAYAMA, 2002, 56 (01) : 1 - 6
  • [6] G/A(1947) polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease
    Xie, T
    Ho, SL
    Li, LSW
    Ma, OCK
    [J]. MOVEMENT DISORDERS, 1997, 12 (03) : 426 - 427
  • [7] DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson's disease treatment
    Sherif, Salma
    Sameh, Ahmed
    Salah, Sohaila Mohammed
    Omar, Amina
    Elhaes, Hanan
    Ibrahim, Asmaa
    Refaat, Ahmed
    Ibrahim, Medhat A.
    [J]. OPTICAL AND QUANTUM ELECTRONICS, 2024, 56 (04)
  • [8] Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease
    Mueller, Thomas
    [J]. DRUGS, 2015, 75 (02) : 157 - 174
  • [9] Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
    Thomas Müller
    [J]. Drugs, 2015, 75 : 157 - 174
  • [10] Catechol-O-methyltransferase inhibitors in Parkinson's disease
    Harper, J
    Vieira, B
    [J]. LANCET, 1998, 352 (9127): : 578 - 578